Compare SCKT & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCKT | SILO |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Apparel |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.1M |
| IPO Year | 1996 | 2011 |
| Metric | SCKT | SILO |
|---|---|---|
| Price | $0.45 | $1.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 57.9K | 34.7K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,078,332.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.22 |
| 52 Week High | $2.79 | $7.95 |
| Indicator | SCKT | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 20.73 |
| Support Level | $0.38 | $0.30 |
| Resistance Level | $0.56 | $4.80 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 6.40 | 0.00 |
Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the United States, Europe, Asia and Rest of the world, of which the majority of the revenue is generated from the United States.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.